Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Business Overview: BioCardia is a clinical-stage biotechnology company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous mononuclear cell therapy for ischemic heart failure and chronic myocardial ischemia, and an allogeneic mesenchymal stem cell therapy. The company also partners on its Helix biotherapeutic delivery system.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $55 |
| Net Loss | $(2,712) | $(2,267) |
| Net Loss Per Share (Basic & Diluted) | $(0.59) | $(1.35) |
| Research & Development Expenses | $1,530 | $1,241 |
| Selling, General & Administrative Expenses | $1,196 | $1,089 |
| Cash and Cash Equivalents (End of Period) | $949 | $949 |
| Net Cash Used in Operating Activities | $(1,618) | $(1,530) |
| Net Cash Provided by Financing Activities | $196 | $1,376 |
| Total Assets | $2,166 | N/A |
| Total Liabilities | $3,686 | N/A |
| Stockholders' Equity (Deficit) | $(1,520) | N/A |
Note: Q1 2024 comparative balance sheet data is not provided in the text, though Q1 2024 income statement and cash flow data are available.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to $0 in Q1 2025 from $55,000 in Q1 2024. The company notes that collaboration revenue is inconsistent and dependent on partner activities.
- Net Loss: Net loss increased by approximately 20% to $2.71 million from $2.27 million year-over-year. However, net loss per share improved significantly to $(0.59) from $(1.35) due to a substantial increase in weighted-average shares outstanding (4.64 million vs. 1.68 million) following a reverse stock split and equity issuances.
- Operating Expenses: Total costs and expenses rose to $2.73 million from $2.33 million. R&D expenses increased by $289,000, primarily driven by closeout activities for the CardiAMP Heart Failure Trial and the start of enrollment in the CardiAMP Heart Failure II Trial.
- Liquidity: Cash balances decreased by $1.42 million during the quarter, ending at $949,000. This contrasts with Q1 2024, where cash decreased by only $154,000.
Outlook, Risks, and Management Commentary
Liquidity and Going Concern
Management has raised substantial doubt about the company's ability to continue as a going concern beyond one year. As of March 31, 2025, cash of $949,000 is insufficient to fund planned expenditures beyond July 2025. The company plans to raise additional capital through debt, equity, or collaboration arrangements, but there is no assurance these will be successful.
Recent Financing and Subsequent Events
- April 2025 Private Placement: Closed April 23, 2025, raising $775,000 gross proceeds via the sale of 406,818 shares and warrants.
- ATM Offerings: Between April 1 and May 13, 2025, the company sold 88,888 shares for $234,000 in gross proceeds.
- ATM Capacity: As of March 31, 2025, approximately $1.1 million remained available under the existing Sales Agreement. This was updated to approximately $1.8 million in April 2025.
Clinical Progress
- CardiAMP HF Trial: Two-year results presented in March 2025 showed increased survival and decreased cardiac events. Data is being shared with the FDA and Japanese regulators.
- CardiAMP HF II: Patient enrollment commenced in April 2025.
- CardiAMP Chronic Myocardial Ischemia: Roll-in cohort results showed improved exercise tolerance and reduced angina episodes.
- CardiALLO (Allogeneic MSC): Low-dose cohort completed with no adverse events; Data Safety Monitoring Board recommended proceeding in April 2025.
Risk Factors
- Nasdaq Delisting Risk: The company received notice on April 1, 2025, of non-compliance with Nasdaq minimum stockholders' equity requirements ($2.5 million) due to a deficit of $837,000 as of December 31, 2024. The company must submit a compliance plan by May 16, 2025, or face delisting.
- Funding Uncertainty: Failure to raise additional capital could force the company to reduce operations, delay trials, or cease operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $949,000 cash balance plus subsequent financing ($1.009 million) to cover operating burn through July 2025 and beyond.
- Nasdaq Compliance Plan: Monitor the submission and acceptance of the plan to regain compliance with Nasdaq listing rules by the May 16, 2025 deadline.
- Capital Raise Execution: Track the success of future equity or debt financings, noting the potential for significant dilution given the current deficit and low cash position.
- Clinical Milestones: Confirm the timeline for FDA/PMDA interactions regarding the CardiAMP HF two-year data and the enrollment progress of the CardiAMP HF II trial.
- Revenue Recognition: Assess the likelihood of future collaboration revenue given the $0 revenue in Q1 2025 and the dependency on partner activities.